Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Policy topic
No spam. Unsubscribe anytime.
Senate moves to pilot preferred drug list for Medicaid after debate on savings and safeguards
Summary
The Senate advanced a substitute version of SB42 to create a pilot preferred drug list (PDL) for Medicaid. Supporters cited multi-state savings and a conservative fiscal estimate; opponents asked for clearer baseline analysis and limits on reinvestment of savings. The Senate read SB42 for the third time (29–0).
The Utah Senate on Feb. 1 advanced Senate Bill 42, a measure to establish a preferred drug list (PDL) pilot for Medicaid, following lengthy floor debate over projected savings, clinical flexibility and oversight.
Sponsor Senator Christiansen argued the Medicaid pharmacy line is growing rapidly and cited examples of large savings in other states. "The price tag for prescription drugs for our Medicaid program is increasing unsustainably," he said, and listed state comparisons and endorsements including the governor, fiscal analysts, the Utah Medical Association and AARP. He urged colleagues to adopt a PDL to protect other programs from cuts.
Members urging caution, including Senator Knudson and Senator Kilpack, sought a stronger baseline analysis from the Department of Health and recommended a pilot with reporting requirements. Kilpack proposed a first-substitute that limits the initial program to six drug classes and sets reporting milestones through 2010; supporters of a targeted pilot argued it allows measurement of savings without an open-ended policy shift.
Senator Bramble and others said the substitute pilot was a responsible path: a two-year managed pilot with required reporting would allow the department to demonstrate savings while preserving clinical discretion for physicians (including a documented dispense-as-written exception). After debate and a motion to substitute that failed, the Senate adopted the final approach and read SB42 for a third time; the tally announced on the floor was 29 yes, 0 nay.
Next steps: The bill requires Department of Health reporting and fiscal monitoring during the pilot period. Lawmakers asked for clear baseline measures of savings and careful oversight to ensure cost reductions do not simply shift costs to other programs or to beneficiaries.
